Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Cingulate Inc. (CING : NSDQ)

• Company Description    Cingulate Inc. is a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release(TM) drug delivery platform technology to build and advance a pipeline of pharmaceutical products. Cingulate Inc. is based in KANSAS CITY, Kan. Number of Employees: 14

• Price / Volume Information    Yesterday's Closing Price: $4.47 Daily Weekly Monthly 20 Day Moving Average: 444,470 shares Shares Outstanding: 13.47 (millions) Market Capitalization: $60.21 (millions) Beta: -0.81 52 Week High: $11.89 52 Week Low: $3.20 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -20.46% -24.35% 12 Week -31.13% -36.33% Year To Date 3.00% 0.41%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1901 W. 47TH PLACE - KANSAS CITY,KS 66205 USA ph: 913-942-2300 fax: - ir@cingulate.com http://www.cingulate.com

• General Corporate Information    Officers Shane J. Schaffer - Chief Executive Officer John A. Roberts - Chairman Laurie A. Myers - Chief Operating Officer and Executive Vice Preside Jennifer L. Callahan - Chief Financial Officer and Executive Vice Preside Jeffrey S. Ervin - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 17248W303 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/18/26 Share - Related Items Shares Outstanding: 13.47 Most Recent Split Date: 8.00 (0.08:1) Beta: -0.81 Market Capitalization: $60.21 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.62 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.44 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/18/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.19 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 8.65% vs. Previous Quarter: -13.10% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -365.15 12/31/25 - -509.72 09/30/25 - -394.49 ROA 03/31/26 - -158.55 12/31/25 - -172.37 09/30/25 - -171.98 Current Ratio 03/31/26 - 2.55 12/31/25 - 1.16 09/30/25 - 1.26 Quick Ratio 03/31/26 - 2.55 12/31/25 - 1.16 09/30/25 - 1.26 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 1.40 12/31/25 - 0.31 09/30/25 - 0.64 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.46 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 31.47 09/30/25 - 0.00

Powered by Zacks Investment Research ©